OREANDA-NEWS. November 1, 2011. RUSNANO co-invests USD 50 million in BIND and Selecta in financing rounds totaling USD 94.5 million to create innovative drugs based on nanomedicine platforms from MIT and Harvard Medical School.

BIND and Selecta establish subsidiaries in Russia to access scientific and clinical expertise that will accelerate development of drugs and drug candidates.

BIND Biosciences and Selecta Biosciences, two leading nanomedicine companies, announced today that they have entered into investment agreements with RUSNANO.

From left to right: Werner Cautreels, Ph.D., President and CEO of Selecta Biosciences, Anatoly Chubais, chairman of the Executive Board of RUSNANO, Scott Minick, CEO of BIND

RUSNANO is co-investing USD 25 million in BIND Biosciences and USD 25 million in Selecta Biosciences, for a total RUSNANO investment of USD 50 million within the total financing rounds of USD 94.5 million in the two companies combined. The remaining co-investments, USD 22.25 million in each company, come from current and new investors of BIND and Selecta.

BIND and Selecta will augment their US-based core operations by establishing subsidiaries in Russia where they will develop their technology platforms in nanomedicine and access the country’s scientific expertise and clinical trial resources. Financing will enable both companies to accelerate and maximize their platforms’ potential for developing multiple drug products. The agreements enable BIND and Selecta to expand into Russia to conduct full-cycle drug development-from R&D through manufacturing and commercialization-and enhance access to high growth pharmaceutical markets.

The proprietary technology platforms of BIND and Selecta originated in laboratories at Harvard Medical School directed by Professor Omid Farokhzad, MD, and in laboratories at MIT directed by Professor Robert Langer, ScD, a renowned scientist who is a recipient of the US National Medal of Science, the highest US honor for scientists, and is an inventor of approximately 850 patents issued or pending worldwide. Drs. Langer and Farokhzad are founders of both companies. Professor Ulrich von Andrian, MD, PhD, head of the immunopathology laboratory at Harvard Medical School, is a founder of Selecta.

Selecta and BIND each has novel technology platforms with the potential to impact global health.

Selecta pioneers new approaches for synthetically engineered vaccines and immunotherapies. Selecta’s lead drug candidate, SEL-068, is entering human clinical studies as a vaccine for smoking cessation and relapse prevention. Other drug development programs include universal human papillomavirus (HPV) vaccine, universal influenza vaccine, malaria vaccine, and type 1 diabetes therapeutic vaccine.

BIND develops targeted therapeutics, called Accurins™ that selectively accumulate at the site of disease to dramatically enhance effectiveness for treating cancer and other diseases. BIND’s lead candidate, BIND-014, is in human clinical trials as a targeted therapy for cancer treatment. BIND’s development pipeline also includes a range of cancer treatments and drugs for anti-inflammatory and cardiovascular conditions.

Anatoly Chubais, chairman of the Executive Board of RUSNANO, commented, "RUSNANO seeks to invest globally in companies with the highest technology potential. We are excited to attract these two leading nanomedicine companies that emerged from laboratories at MIT and Harvard. Our extensive diligence shows that BIND and Selecta have great promise to develop therapeutics that will significantly improve health for the people of Russia and around the world. I believe this transaction will be a catalyst to enhance development and commercialization of novel vaccines and cancer drugs in Russia.”

“I am pleased to welcome RUSNANO as a strategic partner and investor with both BIND and Selecta,” said Noubar Afeyan, Managing Partner and CEO of Flagship Ventures, a founding investor in BIND and Selecta. “We look forward to leveraging the scientific clinical development and financial resources available through these partnerships in order to realize the potential of nanomedicine products to create breakthrough treatments for disease. As two leading-edge biotech companies, BIND and Selecta are joining the pharmaceutical industry’s globalization trends and leveraging opportunities to expand into these high growth markets to accelerate the development of their drug pipelines.”

“We are very excited about the opportunities and possibilities that the Russian market can open to us. Russia is renowned for its highly professional scientists and the country’s focus on innovation. We are looking forward to starting our R&D activities for BIND and Selecta in Russia. Our labs will be up and running in spring of 2012” — said Robert Rosen, CEO of BIND RUS and Selecta RUS.

Terms of the Agreements

According to the terms of the agreements, RUSNANO will invest USD 50 million equally split between Selecta and BIND. As part of the agreements, Selecta and BIND have each established a wholly-owned subsidiary in Moscow, called Selecta (RUS) LLC and BIND (RUS) LLC, respectively. In addition to the investment from RUSNANO, the financing rounds include USD 10 million for each company from all of Selecta’s and BIND’s existing investors as well as other new investors. Participating in these financings are Selecta’s existing investors Polaris Venture Partners, Flagship Ventures, OrbiMed Advisors, NanoDimension, and Leukon Investments and BIND’s existing investors Polaris Venture Partners, ARCH Venture Partners, NanoDimension, DHK Investments, and EndeavourVision. The companies anticipate a second close for the remaining funds, of at least USD 12.25 million in R&D operations of each of the two companies.

“This transaction enables us to expand our global footprint while significantly strengthening Selecta’s pipeline of novel vaccines and immunotherapies,” said Werner Cautreels, Ph.D., President and CEO of Selecta Biosciences. “Our capabilities in Russia give us a competitive position for complementary R&D and manufacturing expertise, as well as the ability to incorporate the needs of patients in emerging markets into our product profiles for vaccines to treat conditions such as nicotine dependence and infectious diseases.”

Scott Minick, CEO of BIND, commented “This is an exceptional opportunity for BIND to expand our pipeline and accelerate the development of our targeted therapeutics for cancer and other diseases. We now have added the combination of a strong investment partner in RUSNANO, the outstanding science and engineering talents in Russia, and a presence in the strategic high-growth global health care arena.”